Results 81 to 90 of about 7,988 (196)

Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single‐Center Retrospective Analysis

Cancer Reports, Volume 8, Issue 10, October 2025.
ABSTRACT Background Hairy cell leukemia (HCL) is a rare disorder characterized by splenomegaly, pancytopenia, and proliferation with “hairy” lymphocytes. Treatment is based on purine analogs and anti‐CD20 antibodies, often resulting in significant adverse effects.
M. Garcia Fasanella, A. Mozos, J. Briones, J. F. Nomdedeu, S. Novelli   +4 more
wiley   +1 more source

Immunotoxins Targeting B cell Malignancy—Progress and Problems With Immunogenicity

Biomedicines, 2018
Few immunotoxins or targeted toxins have become mainline cancer therapies. Still immunotoxins continue to be of major interest and subject of research and development as alternative therapies for drug resistant cancer. A major matter of concern continues
Daniel A. Vallera, Robert J. Kreitman
doaj   +1 more source

Expression of an anti-CD33 single-chain antibody by Pichia pastoris [PDF]

, 2005
CD33 is a cell surface glycoprotein expressed on cells of myelomonocytic lineage, leukaemic cells, but not haematopoietic stem cells. By virtue of its expression pattern, CD33 has become a popular target for new immunotherapeutic approaches to treat ...
Emberson, Louise M., Trivett, Amanda J., Blower, Philip J., Nicholls, Peter J.   +3 more
core   +1 more source

The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations

Toxins, 2017
Ribosome inactivating proteins (RIPs) form a class of toxins that was identified over a century ago. They continue to fascinate scientists and the public due to their very high activity and long-term stability which might find useful applications in the ...
Aleksander Rust, Lynda J. Partridge, Bazbek Davletov, Guillaume M. Hautbergue   +3 more
doaj   +1 more source

Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12 [PDF]

, 2011
Immunotherapy-based strategies for gastrointestinal carcinomas (GIC) have been exploited so far, but these approaches have to face strong mechanisms of immune escape induced by tumours.
Alaniz, Almand, Appay, Barajas, Bell, Beyer, Bluestone, Brodsky, Bronte, Caruso, Catalina Atorrasagasti, Clark, Colombo, Colvin, Croci, Curiel, Dieckmann, Elkord, Ferlay, Flavia Piccioni, Gabrilovich, Gabrilovich, Ghiringhelli, Ghiringhelli, Gomez, Guillermo Mazzolini, Haigh, Huang, Jaime A. Espinoza, Jorge B. Aquino, Juan Bayo, Kerkar, Ko, Larmonier, Laura Alaniz, Leonard, Lorenz, Malvicini, Manuel Gidekel, Mariana Garcia, Mariana Ingolotti, Mariana Malvicini, Matar, Mazzolini, Mazzolini, Mazzolini, Medina-Echeverz, Melero, Nestle, O. Graciela Scharovsky, Onishi, Ormandy, Pablo Matar, Proietti, Putzer, Rabinovich, Sakaguchi, Sangro, Shapira, Spaapen, Suzuki, Takahashi, Tang, Thornton, Trinchieri, Vignali, Yokoyama, Zou, Zou, Zwirner   +69 more
core   +1 more source

EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy

Advanced Science, Volume 12, Issue 36, September 25, 2025.
This review provides new perspectives on EGFR's activation, mutations, and their impact on tumor immunotherapy. It summarizes how EGFR is activated and the current EGFR targeting strategy, evaluates their clinical outcomes in combination with immunotherapy, highlighting differential responses in tumors with EGFR wild‐type and different mutants.
Yuanzhuo Gu, Hongchao He, Shilei Qiao, Yifan Shao, Lurong Wang, Zhengkui Zhang, Long Zhang, Fangfang Zhou   +7 more
wiley   +1 more source

Inclusion of a Furin Cleavage Site Enhances Antitumor Efficacy against Colorectal Cancer Cells of Ribotoxin α-Sarcin- or RNase T1-Based Immunotoxins

Toxins, 2019
Immunotoxins are chimeric molecules that combine the specificity of an antibody to recognize and bind tumor antigens with the potency of the enzymatic activity of a toxin, thus, promoting the death of target cells.
Javier Ruiz-de-la-Herrán, Jaime Tomé-Amat, Rodrigo Lázaro-Gorines, José G. Gavilanes, Javier Lacadena   +4 more
doaj   +1 more source

Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival

MedComm, Volume 6, Issue 9, September 2025.
This is an overview of current and emerging therapeutic strategies for pleural mesothelioma (PM), including chemotherapy, immunotherapy (ICIs, dendritic cell vaccines, CAR‐T therapy), anti‐angiogenic therapy, epigenetic modifications (DNA methylation, histone changes, non‐coding RNAs), and targeted therapy focusing on genomic alterations and signaling ...
Libo Zhang, Meijuan Huang
wiley   +1 more source

Retrograde transport pathways utilised by viruses and protein toxins [PDF]

, 2006
A model has been presented for retrograde transport of certain toxins and viruses from the cell surface to the ER that suggests an obligatory interaction with a glycolipid receptor at the cell surface. Here we review studies on the ER trafficking cholera
Easton, A. J. (Andrew J.), Lord, Mike, Roberts, L. M. (Lynne M.), Smith, Daniel C., Spooner, Robert A.   +4 more
core   +2 more sources

Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME, CDC7 and Ki67

The Journal of Pathology, Volume 267, Issue 1, Page 69-78, September 2025.
Abstract Chondroitin sulfate proteoglycan 4 (CSPG4) is a promising target for melanoma immunotherapy, but its expression in benign melanocytic lesions and its diagnostic value remain unexplored. This study assessed CSPG4 expression in benign nevi (BN), dysplastic nevi (DN), and superficial spreading melanomas (SSM), comparing it with PRAME ...
Elias A T Koch, Christina Seidel, Ramona Erber, Michael Erdmann, Markus V Heppt, Stefan Schliep, Carola Berking, Jan Dörrie, Niels Schaft   +8 more
wiley   +1 more source